Frontida BioPharm, Inc. Announces Highly Potent Compound Contract Manufacturing Suite to Support Existing Product Development and Manufacturing Capabilities
Highly potent compounds serve an increasingly significant role in numerous R&D landscapes and pharmaceutical intensive medical treatments; i.e. oncology, atrial fibrillation, osteoporosis.
FB-HRS, LLC Announces US FDA Clearance of IND Application to Initiate Clinical Trial for FBHRS001, a Treatment for Atrial Fibrillation
Atrial Fibrillation impacts a tremendous amount of people around the world and current treatment options are underwhelming due to negative side effects. FB–HRS, LLC has developed a treatment that may reduce those undesired consequences.
Frontida BioPharm, Inc. and Oncoceutics Inc. announced that the two companies have entered into a product development and commercialization agreement to further develop the finished product manufacturing process for ONC201...